XML 26 R8.htm IDEA: XBRL DOCUMENT v3.22.0.1
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
CASH FLOWS FROM OPERATING ACTIVITIES:      
Net loss $ (48,169) $ (110,861) $ (196,620)
Adjustments to reconcile net loss to cash flows from operating activities:      
Depreciation and amortization 78,652 81,854 80,413
Share-based compensation expense 87,622 90,164 100,977
Deferred income taxes 5,081 9,985 (319)
Change in the fair value of contingent consideration 1,427 (3,945) 22,800
Loss on debt extinguishment 171    
Payment made for debt modification (97)    
Impairment of investment in Synchronicity Pharma, Inc. 977    
Other non-cash charges 1,599 2,514  
Other non-cash charges     (580)
Changes in assets and liabilities:      
Receivables (38,011) (18,050) 35,136
Contract assets 6,037 (6,015) (5,156)
Inventory (24,769) (22,933) (13,077)
Prepaid expenses and other assets 11,481 4,022 (1,784)
Right-of-use assets 17,051 17,336 8,399
Accounts payable and accrued expenses 29,853 50,600 34,847
Contract liabilities (6,080) (4,924) 16,140
Operating lease liabilities (16,777) (16,273) (9,117)
Other long-term liabilities (4,333) 9,368 18
Cash flows provided by operating activities 101,715 82,842 72,077
CASH FLOWS FROM INVESTING ACTIVITIES:      
Additions of property, plant and equipment (28,020) (42,219) (90,942)
Proceeds from the sale of equipment 287 643 900
Proceeds from contingent consideration 7,937 3,886 10,000
Return of Fountain Healthcare Partners II, L.P. investment   2,751  
Payment made for licensed Intellectual Property ("IP") (1,000)    
Purchases of investments (340,418) (229,543) (277,518)
Sales and maturities of investments 295,010 253,001 224,602
Acquisition of Rodin Therapeutics, Inc.'s net assets, net of cash acquired     (8,875)
Cash flows used in investing activities (66,204) (11,481) (141,833)
CASH FLOWS FROM FINANCING ACTIVITIES:      
Proceeds from the issuance of ordinary shares under share-based compensation arrangements 25,319 8,373 18,925
Employee taxes paid related to net share settlement of equity awards (16,571) (7,701) (9,317)
Proceeds from the issuance of long-term debt 23,567    
Payment made for debt extinguishment (993)    
Principal payments of long-term debt (2,250) (2,843) (2,843)
Cash flows provided by (used in) financing activities 29,072 (2,171) 6,765
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS 64,583 69,190 (62,991)
CASH AND CASH EQUIVALENTS—Beginning of period 272,961 203,771 266,762
CASH AND CASH EQUIVALENTS—End of period 337,544 272,961 203,771
SUPPLEMENTAL CASH FLOW DISCLOSURE:      
Cash paid for interest 6,904 8,288 13,254
Cash paid for taxes 1,888 620 2,508
Non-cash investing and financing activities:      
Purchased capital expenditures included in accounts payable and accrued expenses $ 6,025 $ 2,420 $ 13,789